121 related articles for article (PubMed ID: 38158946)
21. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
22. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.
Tada T; Toyoda H; Kumada T; Kurisu A; Sugiyama A; Akita T; Ohisa M; Aikata H; Miki D; Chayama K; Tanaka J
J Viral Hepat; 2021 Mar; 28(3):538-547. PubMed ID: 33215790
[TBL] [Abstract][Full Text] [Related]
23. HCV genotypes and age distribution in patients of Vienna and surrounding areas.
Haushofer AC; Kopty C; Hauer R; Brunner H; Halbmayer WM
J Clin Virol; 2001 Jan; 20(1-2):41-7. PubMed ID: 11163582
[TBL] [Abstract][Full Text] [Related]
24. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
25. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
Tsai PS; Cheng YM; Wang CC; Kao JH
Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
[TBL] [Abstract][Full Text] [Related]
26. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
27. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C.
Myers RP; Patel K; Pianko S; Poynard T; McHutchison JG
J Viral Hepat; 2003 Jan; 10(1):16-22. PubMed ID: 12558907
[TBL] [Abstract][Full Text] [Related]
28. Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment.
Kim JH; Kim MN; Han KH; Kim SU
Liver Int; 2015 Apr; 35(4):1103-15. PubMed ID: 24976523
[TBL] [Abstract][Full Text] [Related]
29. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
[TBL] [Abstract][Full Text] [Related]
30. Significant liver damage in patients with bleeding disorders and chronic hepatitis C: non-invasive assessment of liver fibrosis using transient elastography.
Posthouwer D; Mauser-Bunschoten EP; Fischer K; VAN Erpecum KJ; DE Knegt RJ
J Thromb Haemost; 2007 Jan; 5(1):25-30. PubMed ID: 17239163
[TBL] [Abstract][Full Text] [Related]
31. Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization.
Torres HA; Mahale P
Liver Int; 2015 Jun; 35(6):1661-4. PubMed ID: 25779000
[TBL] [Abstract][Full Text] [Related]
32. Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies.
El-Sayed MH; Mohamed MM; Karim A; Maina AM; Oliveri F; Brunetto MR; Bonino F
Hematol J; 2003; 4(5):321-7. PubMed ID: 14502256
[TBL] [Abstract][Full Text] [Related]
33. Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US.
Wang W; Lo Re V; Guo Y; Xiao H; Brown J; Park H
Aliment Pharmacol Ther; 2020 Nov; 52(10):1592-1602. PubMed ID: 32931606
[TBL] [Abstract][Full Text] [Related]
34. Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals.
Alswat K; Al-Sohaibani F; Khathlan A; Bashmail A; Alanazi M; Kurdi A; Almakadma AH; Al-Hamoudi W
Ann Saudi Med; 2022; 42(2):89-95. PubMed ID: 35380056
[TBL] [Abstract][Full Text] [Related]
35. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis.
Cacciola I; Russo G; Filomia R; Pitrone C; Caccamo G; Giandalia A; Alibrandi A; Stella Franzè M; Porcari S; Maimone S; Saitta C; Squadrito G; Raimondo G
Liver Int; 2021 Sep; 41(9):2059-2067. PubMed ID: 33894103
[TBL] [Abstract][Full Text] [Related]
36. Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection.
Martin-Carbonero L; de Ledinghen V; Moreno A; Maida I; Foucher J; Barreiro P; Romero M; Satta G; Garcia-Samaniego J; Gonzalez-Lahoz J; Soriano V
J Viral Hepat; 2009 Nov; 16(11):790-5. PubMed ID: 19413693
[TBL] [Abstract][Full Text] [Related]
37. Indirect serum fibrosis markers in hepatitis C virus (HCV) infection.
Paunovic K; Stojanovic M; Dimitrijevic Z; Paunovic G; Djordjevic V; Konstantinovic L; Kostic S
Med Arch; 2012; 66(4):226-30. PubMed ID: 22919875
[TBL] [Abstract][Full Text] [Related]
38. HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND SYSTEMIC ARTERIAL HYPERTENSION ARE ASSOCIATED WITH HEPATIC NECROINFLAMMATORY ACTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C.
Souza GHPE; Silva LD; Vieira DA; Rocha GA; Lima AS; Vidigal PVT
Arq Gastroenterol; 2023; 60(3):287-299. PubMed ID: 37792757
[TBL] [Abstract][Full Text] [Related]
39. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
[TBL] [Abstract][Full Text] [Related]
40. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]